Viet Reader.

Loading...

Viet Reader.

VR.

Premier Newspaper for Vietnamese Worldwide

- English
- VietNam

PR Newswire

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma

25-02-2025, 20:00 136 read

Font size Print

Email

$Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG-818 to Treat Relapsed/Refractory Multiple Myeloma$

Kangpu Biopharmaceuticals Received IND Approval from NMPA for KPG 818 to Treat Relapsed Refractory Multiple Myeloma

{fullname}

About author

You should write because you love the shape of stories and sentences and the creation of different words on a page.

View all posts

Related posts

---

U.S. FDA Approves Clinical Trial Application for IASO Bio's BCMA CAR-T CT103A for Relapsed/Refractory Multiple Myeloma

---

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for Treatment of Relapsed/Refractory Multiple Myeloma

---

HanX Biopharmaceuticals announces HX009 IND approval from FDA

---

IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health

SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutics

---

Antengene Announces NDA Submission for XPOVIO® in Macau, Malaysia and Thailand for Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-cell Lymphoma

---

Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma